 | | DRUG: Rabeprazole sodium | |
| Entry |
|
|---|
| Name |
Rabeprazole sodium (JP18/USP);
Aciphex (TN);
Pariet (TN) |
|---|
| Product |
|
|---|
| Generic |
RABEPRAZOLE SODIUM (A-S Medication Solutions), RABEPRAZOLE SODIUM (A-S Medication Solutions), RABEPRAZOLE SODIUM (Advagen Pharma Limited), RABEPRAZOLE SODIUM (Advanced Rx Pharmacy of Tennessee), RABEPRAZOLE SODIUM (Advanced Rx Pharmacy of Tennessee), RABEPRAZOLE SODIUM (Advanced Rx Pharmacy of Tennessee), RABEPRAZOLE SODIUM (Amneal Pharmaceuticals LLC), RABEPRAZOLE SODIUM (Ascend Laboratories), RABEPRAZOLE SODIUM (Asclemed USA), RABEPRAZOLE SODIUM (Asclemed USA), RABEPRAZOLE SODIUM (Aurobindo Pharma Limited), RABEPRAZOLE SODIUM (Bryant Ranch Prepack), RABEPRAZOLE SODIUM (Bryant Ranch Prepack), RABEPRAZOLE SODIUM (Bryant Ranch Prepack), RABEPRAZOLE SODIUM (Chartwell RX), RABEPRAZOLE SODIUM (DIRECT RX), RABEPRAZOLE SODIUM (DIRECT RX), RABEPRAZOLE SODIUM (Golden State Medical Supply), RABEPRAZOLE SODIUM (Lannett Company), RABEPRAZOLE SODIUM (Medsource Pharmaceuticals), RABEPRAZOLE SODIUM (Medsource Pharmaceuticals), RABEPRAZOLE SODIUM (Preferred Pharmaceuticals), RABEPRAZOLE SODIUM (Preferred Pharmaceuticals), RABEPRAZOLE SODIUM (Preferred Pharmaceuticals), RABEPRAZOLE SODIUM (Proficient Rx LP), RABEPRAZOLE SODIUM (Proficient Rx LP), RABEPRAZOLE SODIUM (Proficient Rx LP), RABEPRAZOLE SODIUM (Proficient Rx LP), RABEPRAZOLE SODIUM (Proficient Rx LP), RABEPRAZOLE SODIUM (Quality Care Products), RABEPRAZOLE SODIUM (REMEDYREPACK), RABEPRAZOLE SODIUM (REMEDYREPACK), RABEPRAZOLE SODIUM (St. Mary's Medical Park Pharmacy), RABEPRAZOLE SODIUM (Torrent Pharmaceuticals Limited), RABEPRAZOLE SODIUM (medsource pharmaceuticals), RABERPRAZOLE SODIUM D/R (Direct_Rx) |
|---|
| Formula |
C18H20N3O3S. Na
|
|---|
| Exact mass |
381.1123
|
|---|
| Mol weight |
381.4245
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2329 |
| Product (DG00022): | D00724<JP/US> |
| Product (mixture): | D10519<JP> D10520<JP> |
|
|---|
| Efficacy |
Antisecretory (gastric acid), Anti-ulcerative, Proton pump inhibitor |
|---|
| Disease |
Erosive or ulcerative GERD [DS: H01602] Duodenal ulcer [DS: H01634] Helicobacter pylori eradication [DS: H00320] Zollinger-Ellison syndrome [DS: H01522] |
|---|
| Comment |
Benzimidazole derivative
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C19 [HSA: 1557], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BC Proton pump inhibitors
A02BC04 Rabeprazole
D00724 Rabeprazole sodium (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Proton Pump Inhibitors
Rabeprazole
D00724 Rabeprazole sodium (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
232 Peptic ulcer agents
2329 Others
D00724 Rabeprazole sodium (JP18/USP)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
DG00022 Rabeprazole
D00724 Rabeprazole sodium
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG00022 Rabeprazole
D00724 Rabeprazole sodium
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00022 Rabeprazole
D00724 Rabeprazole sodium
Drug classes [BR:br08332]
Gastrointestinal agent
DG01646 Proton pump inhibitor (PPI)
D00724 Rabeprazole sodium
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
ATPase
ATP4
D00724 Rabeprazole sodium (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00724 Rabeprazole sodium
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00724
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00724
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00724
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00724
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
DG00022 Rabeprazole
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG00022 Rabeprazole
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00022 Rabeprazole
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 26
1 Z Na 14.9181 -21.7880 #+
2 C8x C 11.7600 -23.5900
3 C8x C 11.7600 -24.9900
4 C8x C 12.9724 -25.6900
5 C8y C 14.1849 -24.9900
6 C8y C 14.1849 -23.5900
7 C8x C 12.9724 -22.8900
8 N5x N 15.5164 -25.4226
9 C8y C 16.3393 -24.2900
10 N4x N 15.5164 -23.1574 #-
11 S4a S 17.7100 -24.2900
12 C1b C 18.4100 -25.5024
13 O3c O 18.4100 -23.0776
14 C8y C 19.8098 -25.5024
15 C8y C 20.5003 -26.6980
16 C8y C 21.9003 -26.6978
17 C8x C 22.6001 -25.4853
18 C8x C 21.9097 -24.2898
19 N5x N 20.5097 -24.2899
20 C1a C 19.8149 -27.8852
21 O2a O 22.5910 -27.8932
22 C1b C 24.0096 -27.8932
23 C1b C 24.6956 -29.0806
24 C1b C 26.1097 -29.0806
25 O2a O 26.7968 -30.2700
26 C1a C 28.2097 -30.2699
BOND 27
1 2 3 2
2 3 4 1
3 4 5 2
4 5 6 1
5 6 7 2
6 2 7 1
7 5 8 1
8 8 9 2
9 9 10 1
10 6 10 1
11 9 11 1
12 11 12 1
13 11 13 2
14 12 14 1
15 14 15 2
16 15 16 1
17 16 17 2
18 17 18 1
19 18 19 2
20 14 19 1
21 15 20 1
22 16 21 1
23 21 22 1
24 22 23 1
25 23 24 1
26 24 25 1
27 25 26 1
|
|---|
|
» Japanese version » Back
|
|